Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Akari Therapeutics, Plc Stock Quote

Akari Therapeutics, Plc (NASDAQ: AKTX)

$1.19
(0.0%)
$0.00
Price as of April 25, 2024, 3:56 p.m. ET

Akari Therapeutics, Plc Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
AKTX -68.68% -98.33% -55.89% -100%
S&P +24.56% +72.51% +11.52% +170%

Akari Therapeutics, Plc Company Info

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.